|
End-of-day quote
Nasdaq
17/11/2026
|
5-day change | 1st Jan Change | ||
| 1.720 USD | -8.99% |
|
+2.99% | -80.95% |
| 11-16 | EnGene Therapeutics Inc. Presents at UBS Global Biopharma Conference 2026, Nov-16-2026 03:20 PM | |
| 11-13 | Leerink Partners Upgrades enGene to Outperform From Market Perform, $5 Price Target | MT |
Chart: Technical Analysis
NasdaqUSD
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| ENGN | End-of-day quote | |
| ENGN | Real-time | ||
| S0N0 | Delayed |
Technical analysis trends
| Short Term | Mid-Term | Long Term | |
|---|---|---|---|
| Trend | Neutral | Neutral | Bearish |
| Resistance | 2.41 | 2.41 | 4.24 |
| Spread/Res. | -28.63% | -28.63% | -59.43% |
| Spread/Supp. | +18.62% | +18.62% | +14.67% |
| Support | 1.45 | 1.45 | 1.5 |
MarketScreener's Technical Analysis Ratings
| Short Term Timing | |
|---|---|
| Middle Term Timing | |
| Long Term Timing | |
| RSI | |
| Bollinger Spread | |
| Unusual Volumes |
- Stock Market
- Stocks
- ENGN Stock
- Charts enGene Therapeutics Inc.
Select your edition
All financial news and data tailored to specific country editions
















